What is the equity of Cosmos Pharmaceutical this year?
Cosmos Pharmaceutical has equity of 231.44 B JPY this year.
In 2024, Cosmos Pharmaceutical's equity was 231.44 B JPY, a 21.49% increase from the 190.51 B JPY equity in the previous year.
Cosmos Pharmaceutical's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cosmos Pharmaceutical's equity is essential for assessing its financial health, stability, and value to shareholders.
Evaluating Cosmos Pharmaceutical's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Cosmos Pharmaceutical's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Fluctuations in Cosmos Pharmaceutical’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Cosmos Pharmaceutical has equity of 231.44 B JPY this year.
The equity of Cosmos Pharmaceutical has increased/decreased by 21.49% increased compared to the previous year.
A high equity is advantageous for investors of Cosmos Pharmaceutical as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
A low equity can be a risk for investors of Cosmos Pharmaceutical, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
An increase in equity of Cosmos Pharmaceutical can strengthen the company's financial position and improve its ability to make investments in the future.
A reduction in equity of Cosmos Pharmaceutical can affect the financial situation of the company and lead to a higher dependence on debt capital.
Some factors that can affect the equity of Cosmos Pharmaceutical include profits, dividend payments, capital increases, and acquisitions.
The equity of Cosmos Pharmaceutical is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
To change equity, Cosmos Pharmaceutical can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
Over the past 12 months, Cosmos Pharmaceutical paid a dividend of 92.5 JPY . This corresponds to a dividend yield of about 1.28 %. For the coming 12 months, Cosmos Pharmaceutical is expected to pay a dividend of 101.34 JPY.
The current dividend yield of Cosmos Pharmaceutical is 1.28 %.
Cosmos Pharmaceutical pays a quarterly dividend. This is distributed in the months of December, June, December, June.
Cosmos Pharmaceutical paid dividends every year for the past 23 years.
For the upcoming 12 months, dividends amounting to 101.34 JPY are expected. This corresponds to a dividend yield of 1.4 %.
Cosmos Pharmaceutical is assigned to the 'Non-cyclical consumption' sector.
To receive the latest dividend of Cosmos Pharmaceutical from 2/1/2025 amounting to 32.5 JPY, you needed to have the stock in your portfolio before the ex-date on 11/28/2024.
The last dividend was paid out on 2/1/2025.
In the year 2023, Cosmos Pharmaceutical distributed 117.5 JPY as dividends.
The dividends of Cosmos Pharmaceutical are distributed in JPY.
Our stock analysis for Cosmos Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cosmos Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.